Correlation Between Arvinas and Stoke Therapeutics

Can any of the company-specific risk be diversified away by investing in both Arvinas and Stoke Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Arvinas and Stoke Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Arvinas and Stoke Therapeutics, you can compare the effects of market volatilities on Arvinas and Stoke Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Arvinas with a short position of Stoke Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Arvinas and Stoke Therapeutics.

Diversification Opportunities for Arvinas and Stoke Therapeutics

0.6

Correlation Coefficient

Arvinas  Stoke Therapeutics

Poor diversification

The 3 months correlation between Arvinas and Stoke is 0.6. Overlapping area represents the amount of risk that can be diversified away by holding Arvinas and Stoke Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Stoke Therapeutics and Arvinas is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Arvinas are associated (or correlated) with Stoke Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Stoke Therapeutics has no effect on the direction of Arvinas i.e., Arvinas and Stoke Therapeutics go up and down completely randomly.

Pair Corralation between Arvinas and Stoke Therapeutics

Given the investment horizon of 90 days Arvinas is expected to under-perform the Stoke Therapeutics. In addition to that, Arvinas is 1.6 times more volatile than Stoke Therapeutics. It trades about -0.14 of its total potential returns per unit of risk. Stoke Therapeutics is currently generating about -0.1 per unit of volatility. If you would invest  1,080  in Stoke Therapeutics on December 29, 2024 and sell it today you would lose (335.00) from holding Stoke Therapeutics or give up 31.02% of portfolio value over 90 days.

Time Period	3 Months [change]
Direction	Moves Together
Strength	Significant
Accuracy	100.0%
Values	Daily Returns

Arvinas  vs.  Stoke Therapeutics

Arvinas

Risk-Adjusted Performance

Very Weak

Over the last 90 days Arvinas has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of unsteady performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in April 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Stoke Therapeutics

Risk-Adjusted Performance

Very Weak

Over the last 90 days Stoke Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain quite persistent which may send shares a bit higher in April 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors.

Pair Trading with Arvinas and Stoke Therapeutics

The main advantage of trading using opposite Arvinas and Stoke Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Arvinas position performs unexpectedly, Stoke Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Stoke Therapeutics will offset losses from the drop in Stoke Therapeutics' long position.

The idea behind Arvinas and Stoke Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Global Markets Map module to get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes.